Medifast (MED) Reports In-Line Q3 EPS, Offers Guidance

Medifast (NYSE: MED) reported Q3 EPS of $1.14, in-line with the analyst estimate of $1.14. Revenue for the quarter came in at $139.2 million versus the consensus estimate of $125.81 million.

GUIDANCE:

Medifast sees Q4 2018 EPS of $1.15-$1.20, versus the consensus of $1.16. Medifast sees Q4 2018 revenue of $137.3-142.3 million, versus the consensus of $130.15 million.

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance